NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis

Abstract

Management of patient with Lupus Nephritis (LN) continues to remain a challenge for the treating physicians because of considerable morbidity and even mortality. The search of biomarkers in serum and urine is a focus of researchers to unravel new targets for therapy. In the present study, the utility of NMR-based serum metabolomics has been evaluated for the first time in discriminating LN patients from non-nephritis lupus patients (SLE) and further to get new insights into the underlying disease processes for better clinical management. Metabolic profiling of sera obtained from 22 SLE patients, 40 LN patients and 30 healthy controls (HC) were performed using high resolution 1D 1H-CPMG and diffusion edited NMR spectra to identify the potential molecular biomarkers. Using multivariate analysis, we could distinguish SLE and LN patients from HC and LN from SLE patients. Compared to SLE patients, the LN patients had increased serum levels of lipid metabolites (including LDL/VLDL lipoproteins), creatinine and decreased levels of acetate. Our results revealed that metabolic markers especially lipids and acetate derived from NMR spectroscopy has high sensitivity and specificity to distinguish LN among SLE patients and has the potential to be a useful adjunctive tool in diagnosis and clinical management of LN.

Alpha-linolenic acid stabilizes HIF-1 α and downregulates FASN to promote mitochondrial apoptosis for mammary gland chemoprevention

“…Inflammation is a most common clinical manifestation of various cancer types and triggers a hyper-catabolic state, resulting in increased energy requirements. Consistent with this phenomenon the increased concentrations of serum acetyl-glycoproteins (both NAG and OAG) (acute phase anti-inflammatory proteins expressed during inflammation and immune response) was recorded after the DMBA treatment and is in line with previous investigations in liver disease, inflammatory disease, and cancer [ 35 – 37 ]. As expected, ALA (an anti-inflammatory PUFA) curtailed the expression of acute phase proteins expressed during inflammation [ 38 ].…”

Urinary Metabolomic Profiling to Identify Potential Biomarkers for the Diagnosis of Behcet’s Disease by Gas Chromatography/Time-of-Flight−Mass Spectrometry

“…Metabolomic analysis can be performed using easily accessible biofluids such as urine, blood or cerebrospinal fluid and may permit the identification of disease-specific metabolite signatures that may be useful as disease biomarkers. Several metabolomic studies of BD, rheumatoid arthritis (RA), or lupus nephritis have been performed using various analytical platforms and biologic fluids [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ].…”

1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages

“…Serum samples (200 µL) were processed according to standard procedures for NMR metabolomics measurement [8,9,54]. Briefly, prior to NMR analysis, sera were thawed at room temperature, and an aliquot of 200 µL was added of 400 µL of saline buffer solution (NaCl 0.9%, 50 mM sodium phosphate buffer in D 2 O containing TSP 0.05% wt for chemical shift calibration, pH 7.4) to minimize the variation in pH and transferred in a 5 mm NMR tube [54][55][56]. The NMR experiments were recorded on a Bruker Avance III NMR spectrometer (Bruker, Ettlingen, Germany), operating at 600.13 MHz for 1 H observation, equipped with a TCI cryoprobe (Triple Resonance inverse Cryoprobe), incorporating a z-axis gradient coil and automatic tuning-matching (Supplementary: Section S1).…”